Our Co-Founder and CSO Dr. Alberto Lázaro has just published a Commentary in the Kidney International Journal, the official journal of the International Society of Nephrology. KI is one of the most cited journals in nephrology and widely regarded as the world’s premier journal on the development and consequences of kidney disease. The paper highlights the relevance of Cilastatin as a new therapeutic promise for acute kidney injury (AKI). This article is a recognition to the whole team of the Renal Physiopathology Laboratory of the Instituto de Investigación Sanitaria Gregorio Marañón that contributed to the preclinical development of cilastatin as a nephroprotective drug. Special thanks to its founder, Dr. Alberto Tejedor, may he rest in peace, for all his efforts in the research of AKI and the drug Cilastatin.
The evidence supports the potential use of cilastatin as either a direct nephroprotectant or an endocytic adaptor to enhance the renal specificity of drug-loaded nanoparticles designed for AKI treatment. Cilastatin safety has been established through its use in combination with imipenem since 1985, and a dose-escalating phase 1 clinical trial was completed in 2018 to assess the safety of higher doses of cilastatin (NCT03595189), yielding favorable safety results.
Currently, 2 clinical trials with cilastatin are in progress. Our partner Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB) is leading the PONTIAC Phase II trial a 900-patient study targeting AKI caused by drug toxins. Full release: https://lnkd.in/ghNWcfdQ. And a phase 2 clinical trials for cisplatin nephroprotection (EudraCT number: 2022-001417-39) being performed at Fundación para la investigación biomédica del Hospital Gregorio Marañón (FIBHGM).
You can download the paper for a limited time here: https://lnkd.in/dGMxktaR